90.36
-0.71 (-0.78%)
| Penutupan Terdahulu | 91.07 |
| Buka | 91.07 |
| Jumlah Dagangan | 2,344,312 |
| Purata Dagangan (3B) | 2,040,042 |
| Modal Pasaran | 11,852,561,408 |
| Harga / Jualan (P/S) | 11.63 |
| Harga / Buku (P/B) | 55.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -53.82% |
| Margin Operasi (TTM) | -54.33% |
| EPS Cair (TTM) | -3.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.80% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | -272.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.71 M |
| Pulangan Atas Aset (ROA TTM) | -18.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -4,584.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Guardant Health, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 3.0 |
| Purata | 0.00 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.53% |
| % Dimiliki oleh Institusi | 97.57% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 180.00 (Leerink Partners, 99.20%) | Beli |
| Median | 132.50 (46.64%) | |
| Rendah | 110.00 (Evercore ISI Group, 21.74%) | Pegang |
| Purata | 135.42 (49.87%) | |
| Jumlah | 11 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 103.76 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 24 Feb 2026 | 130.00 (43.87%) | Beli | 95.40 |
| BTIG | 20 Feb 2026 | 145.00 (60.47%) | Beli | 103.10 |
| Canaccord Genuity | 20 Feb 2026 | 135.00 (49.40%) | Beli | 103.10 |
| Citigroup | 20 Feb 2026 | 150.00 (66.00%) | Beli | 103.10 |
| Evercore ISI Group | 20 Feb 2026 | 110.00 (21.74%) | Pegang | 103.10 |
| JP Morgan | 20 Feb 2026 | 130.00 (43.87%) | Beli | 103.10 |
| Leerink Partners | 20 Feb 2026 | 180.00 (99.20%) | Beli | 103.10 |
| Stifel | 20 Feb 2026 | 130.00 (43.87%) | Beli | 103.10 |
| TD Cowen | 20 Feb 2026 | 135.00 (49.40%) | Beli | 103.10 |
| Wells Fargo | 20 Feb 2026 | 125.00 (38.34%) | Beli | 103.10 |
| Baird | 17 Feb 2026 | 120.00 (32.80%) | Beli | 107.11 |
| Guggenheim | 26 Jan 2026 | 135.00 (49.40%) | Beli | 114.74 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SAIA JOHN G. | - | 84.86 | -3,970 | -336,894 |
| TARIQ MUSA | - | 85.70 | -116 | -9,941 |
| Jumlah Keseluruhan Kuantiti Bersih | -4,086 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -346,835 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 85.28 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TARIQ MUSA | Pengarah | 16 Apr 2026 | Jual (-) | 116 | 85.70 | 9,941 |
| SAIA JOHN G. | Pegawai | 15 Apr 2026 | Dibuang (-) | 3,970 | 84.86 | 336,894 |
| SAIA JOHN G. | Pegawai | 15 Apr 2026 | Pelaksanaan pilihan | 7,569 | - | - |
| TARIQ MUSA | Pengarah | 15 Apr 2026 | Pelaksanaan pilihan | 250 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |